(Q54677635)

2 June 2018

title

Immune checkpoint inhibitors in malignant pleural mesothelioma. (English)

1 reference

2 June 2018

author name string

Giovanni Luca Ceresoli

series ordinal

1

1 reference

2 June 2018

Alberto Mantovani

series ordinal

2

1 reference

2 June 2018

publication date

1 May 2017

1 reference

2 June 2018

Lancet Oncology Commission

published in

1 reference

2 June 2018

volume

18

1 reference

2 June 2018

page(s)

559-561

1 reference

2 June 2018

issue

5

1 reference

2 June 2018

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

Tumour-associated macrophages as treatment targets in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930191-2

7 January 2021

10.1016/S1470-2045(17)30191-2

Identifiers

DOI

1 reference

2 June 2018

PubMed ID

28495276

1 reference

2 June 2018